Various prospective cohort studies have been published involving diverse patient groups and variable stimulation protocols, and deliver conflicting results, with no clear benefit of luteal phase GnRH antagonists demonstrated with regard to the incidence of OHSS (94, 95). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.